Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme

OBJECTIVES: In 2013, the herpes zoster (HZ) immunisation programme was introduced in the UK, recommending vaccination of adults 70 years of age (YOA) with the zoster vaccine live (ZVL), the only vaccine available at the time. The recently approved adjuvanted recombinant zoster vaccine (RZV) has a su...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: van Oorschot, Desirée A M, Hunjan, Manjit, Bracke, Benjamin, Lorenc, Stéphane, Curran, Desmond, Starkie-Camejo, Helen
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Health Policy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6502027/
https://ncbi.nlm.nih.gov/pubmed/31061027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-025553
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados